Literature DB >> 22028477

Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation.

Enrico Tiacci1, Gianluca Schiavoni, Francesco Forconi, Alessia Santi, Livio Trentin, Achille Ambrosetti, Debora Cecchini, Elisa Sozzi, Paola Francia di Celle, Cristiana Di Bello, Alessandro Pulsoni, Robin Foà, Giorgio Inghirami, Brunangelo Falini.   

Abstract

Hairy cell leukemia (HCL) is a distinct clinicopathologic entity that responds well to purine analogs but is sometimes difficult to differentiate from HCL-like disorders (e.g., splenic marginal zone lymphoma and HCL variant). We recently identified the BRAF-V600E mutation as the disease-defining genetic event in HCL. In this study, we describe a new, simple, and inexpensive test for genetics-based diagnosis of HCL in whole-blood samples that detects BRAF-V600E through a sensitive allele-specific PCR qualitative assay followed by agarose-gel electrophoresis. This approach detected BRAF-V600E in all 123 leukemic HCL samples investigated containing as few as 0.1% leukemic cells. BRAF-V600E was detected at different time points during the disease course, even after therapy, pointing to its pivotal role in HCL pathogenesis and maintenance of the leukemic clone. Conversely, 115 non-HCL chronic B-cell neoplasms, including 79 HCL-like disorders, were invariably negative for BRAF-V600E. This molecular assay is a powerful tool for improving the diagnostic accuracy in HCL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22028477     DOI: 10.1182/blood-2011-08-371179

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

1.  Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.

Authors:  Luca Arcaini; Davide Rossi
Journal:  Haematologica       Date:  2012-05       Impact factor: 9.941

Review 2.  Hairy cell leukemia: update and current therapeutic approach.

Authors:  Latif Salam; Omar Abdel-Wahab
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

3.  Tumor Type-Agnostic Treatment and the Future of Cancer Therapy.

Authors:  Luis E Raez; Edgardo S Santos
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

4.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Authors:  Giulia Siravegna; Benedetta Mussolin; Michela Buscarino; Giorgio Corti; Andrea Cassingena; Giovanni Crisafulli; Agostino Ponzetti; Chiara Cremolini; Alessio Amatu; Calogero Lauricella; Simona Lamba; Sebastijan Hobor; Antonio Avallone; Emanuele Valtorta; Giuseppe Rospo; Enzo Medico; Valentina Motta; Carlotta Antoniotti; Fabiana Tatangelo; Beatriz Bellosillo; Silvio Veronese; Alfredo Budillon; Clara Montagut; Patrizia Racca; Silvia Marsoni; Alfredo Falcone; Ryan B Corcoran; Federica Di Nicolantonio; Fotios Loupakis; Salvatore Siena; Andrea Sartore-Bianchi; Alberto Bardelli
Journal:  Nat Med       Date:  2015-06-01       Impact factor: 53.440

Review 5.  Lynch syndrome: clinical, pathological, and genetic insights.

Authors:  Ralph Schneider; Claudia Schneider; Matthias Kloor; Alois Fürst; Gabriela Möslein
Journal:  Langenbecks Arch Surg       Date:  2012-02-24       Impact factor: 3.445

6.  A quantitative allele-specific PCR test for the BRAF V600E mutation using a single heterozygous control plasmid for quantitation: a model for qPCR testing without standard curves.

Authors:  Philippe Szankasi; N Scott Reading; Cecily P Vaughn; Josef T Prchal; David W Bahler; Todd W Kelley
Journal:  J Mol Diagn       Date:  2013-01-08       Impact factor: 5.568

7.  Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Hossein Khiabanian; Valeria Spina; Carmela Ciardullo; Alessio Bruscaggin; Rosella Famà; Silvia Rasi; Sara Monti; Clara Deambrogi; Lorenzo De Paoli; Jiguang Wang; Valter Gattei; Anna Guarini; Robin Foà; Raul Rabadan; Gianluca Gaidano
Journal:  Blood       Date:  2014-02-05       Impact factor: 22.113

8.  Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.

Authors:  L Xu; Z R Hunter; G Yang; Y Cao; X Liu; R Manning; C Tripsas; J Chen; C J Patterson; M Kluk; S Kanan; J Castillo; N Lindeman; S P Treon
Journal:  Leukemia       Date:  2014-02-10       Impact factor: 11.528

Review 9.  Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond.

Authors:  Richard Rosenquist; Andreas Rosenwald; Ming-Qing Du; Gianluca Gaidano; Patricia Groenen; Andrew Wotherspoon; Paolo Ghia; Philippe Gaulard; Elias Campo; Kostas Stamatopoulos
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

Review 10.  Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.

Authors:  Frank S Ong; Kingshuk Das; Jay Wang; Hana Vakil; Jane Z Kuo; Wendell-Lamar B Blackwell; Stephen W Lim; Mark O Goodarzi; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.